FDA Warning Letter, China API Supplier: Check by Site

A closed-out FDA warning letter at one Aurobindo facility does not clear the other facilities operating under the same corporate name. Wholesale buyers screening offshore API suppliers have to track compliance status by FDA facility identifier, not by the name on the letterhead.

FDA does not record enforcement by company name. The agency's public warning letter database lists actions against named legal entities tied to specific inspected establishments, and two establishments under one corporate parent carry two independent compliance histories. A procurement check built around a company name alone will miss that distinction. The Aurobindo file is the cleanest worked example on the public record: one facility number received a warning letter in 2019 and a close-out in 2023, and a differently numbered facility under a near-identical corporate name received its own warning letter in 2022.^1,2,3

Two warning letters, two facility numbers, one corporate name

The FDA warning letter dated June 20, 2019 and posted to the agency's public database was issued to Aurobindo Pharma Limited, facility identifier 577033, citing current good manufacturing practice deficiencies. That letter is the one most commonly surfaced by a name-based search, because it is the older document and the one that eventually received a close-out. A buyer who stops reading there concludes that the enforcement question at Aurobindo has been resolved and files the matter under settled history.¹

It has not been settled across the corporate group. On January 12, 2022, FDA issued a separate warning letter to Aurobindo Pharmaceutical Limited, indexed under facility number 618091. That letter followed the agency's review of the firm's August 12, 2021 response to a Form FDA 483 and cited failures in change-management and deviation-investigation systems. Change control and deviation investigation are the two systems a wholesale buyer relies on most directly, because they govern whether a manufacturing alteration ever reaches the paperwork that accompanies a shipment.²

The two entity names differ by a single inflected word. In a procurement system that stores suppliers as free text, they collapse into one record. Once collapsed, the close-out attached to 577033 is inherited by material that never came from 577033 at all, and the 2022 action against 618091 disappears from the buyer's view of the relationship.^1,2

What the February 2023 close-out letter actually closes

FDA issued a close-out letter dated February 9, 2023 for Aurobindo Pharma Limited, facility 577033, evaluating the corrective actions the firm took in response to the June 20, 2019 warning letter. The scope of that document is exactly as narrow as its heading: one facility number, one prior letter. Nothing in it speaks to 618091, and nothing in it speaks to any inspectional finding that never escalated to warning-letter level.⁴

The letter is also conditional on its own terms. It states that while the firm's corrective actions appeared adequate, future FDA inspections would further assess the sustainability of those corrections, and that the letter did not relieve the firm of responsibility for continued compliance. That is a forward-looking reservation, not a clearance. A close-out establishes that the specific deficiencies cited in 2019 were addressed to the agency's satisfaction as of February 2023. It establishes nothing about the state of the quality system in the quarter a purchase order is actually cut.⁴

The Form 483 layer underneath the letters

Warning letters are the visible tier of a deeper stack. FDA's CDER FOIA Electronic Reading Room holds a compliance record for Aurobindo Pharma Ltd. Unit VI dated September 1, 2017, documenting inspectional findings at that site. The published record for Unit VI is a separate document from either warning letter and carries no close-out, because inspectional observations that do not escalate do not generate one.^5,10

The same reading room holds a Form FDA 483 issued to Aurobindo Pharma Ltd. Unit V in Telangana, India, dated October 28, 2019, and a Form FDA 483 for an Aurobindo Pharma Ltd. facility in Telangana dated May 24, 2019. Both fall within months of the June 2019 warning letter, and neither is disposed of by the February 2023 close-out, which addresses only the 2019 letter at 577033.^6,9,4

There is a domestic layer as well. The reading room holds a compliance document for Aurobindo Pharma USA Inc. dated May 15, 2024 — a distinct legal entity in the distribution chain, inspected on its own schedule. For a reseller sourcing finished vials or bulk material through a US-registered arm, that entity's record is as relevant as the foreign manufacturing site's.⁷

• Unit VI compliance record, September 1, 2017 — inspectional findings, no close-out on the public record.
• Telangana facility Form FDA 483, May 24, 2019 — observations published in full.
• Unit V, Telangana, Form FDA 483, October 28, 2019 — issued after the June 2019 warning letter.
• Aurobindo Pharma USA Inc. compliance document, May 15, 2024 — separate entity, separate inspection.
• Facility 618091 warning letter, January 12, 2022 — issued after review of an August 12, 2021 Form 483 response.^2,5,6,7,9,10

Why a supplier certificate can't substitute for a site-level check

A reseller's own documentation package — supplier questionnaire, quality agreement, certificate of analysis for the lot in hand — describes what the seller says about the material. FDA's warning letter database describes what the agency says about the establishment that made it. The database spans all FDA-regulated industries, including pharmaceutical manufacturers. No supplier-issued certificate outranks it, and no quality agreement clause converts an open action at one site into a clean status.³

The volume matters here too. FDA's public search results for drug-center warning letters run to multiple pages of paginated archive. A supplier file built from a single search performed at onboarding is a snapshot of a moving record.⁸

The consequence lands on the entry line. When the identifier attached to an incoming shipment resolves to a facility with an unresolved action, the paperwork the importer holds is not the paperwork that decides the question. Detention risk sits upstream of the reseller's file, in a database the reseller does not control and can only read.^3,8

What to request before the next purchase order

The distinction between corporate name and facility identifier converts into a short document ask. Every item below is verifiable against records FDA has already published, which means a supplier that declines to produce them is declining to be checked.^1,2,4

1. The FDA facility identifier — the FEI or establishment number — for the specific site that manufactured the lot being quoted, in writing, on the quote itself rather than in correspondence.
2. The warning letter history for that identifier alone. Facility 577033 and facility 618091 are separate lines in the file, not two views of one company.
3. Any close-out letter matching that identifier, with its date. The February 9, 2023 close-out applies to 577033 and to the June 20, 2019 letter, and to nothing else.
4. The Form FDA 483 record for the site, including observations that never escalated — the Unit VI record of September 1, 2017 and the Unit V record of October 28, 2019 exist independently of any warning letter.
5. The firm's Form 483 response documentation and its date, since the January 12, 2022 letter at 618091 issued after FDA reviewed an August 12, 2021 response and found the change-management and deviation systems still deficient.
6. The record for the US-registered entity in the chain, separately — the Aurobindo Pharma USA Inc. compliance document of May 15, 2024 sits on its own inspection track.^{1,2,4,5,6,7,9,10}

A dual-sourcing arrangement has to be tested against the same numbering. Two units under one corporate parent are not automatically two sources merely because the name on the letterhead differs by an inflected word; each carries its own facility identifier and its own enforcement history until shown otherwise. Genuine redundancy means two distinct facility identifiers with independent enforcement histories, and preferably two unrelated parents.²

Setting a re-qualification cadence instead of a one-time check

Because the warning letter database is maintained and updated continuously across all FDA-regulated industries, a supplier qualification performed once at onboarding decays from the day it is signed. The 618091 letter of January 12, 2022 would have been invisible to any file frozen in 2021, and the February 9, 2023 close-out would have been invisible to a file frozen in 2022 — in both directions, the stale record misstates the position.^3,4

A quarterly re-check is the practical floor, run per facility identifier rather than per supplier name, with the result dated and archived alongside the purchase orders it covers. That interval matches the pace at which the drug-center archive accumulates new letters and keeps the file defensible if an entry line is questioned months after a shipment cleared.^8,3

• Store suppliers in the qualification system keyed to facility identifier, with the corporate name as a secondary field.
• Re-run the warning letter and close-out check quarterly for every active identifier, and record the date the check was run.
• Treat a close-out as dated evidence about specific prior deficiencies, not as a standing clearance for the site.
• Re-open qualification on any new Form 483 for the site, whether or not it escalates to a letter.